Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Share subscriptions based on stock options 2020 II
Aiforia Technologies Plc, Company release, April 16, 2025 09:00 a.m. EEST
A total of 28,300 Aiforia Technologies Plc’s new shares have been subscribed for with the Stock Options 2020 II on 13 April 2025.
For subscriptions made with the stock options 2020 II the entire subscription price of
EUR 38 838,92 will be entered into the reserve for invested unrestricted equity. After the trade registration the total number of shares is 28,962,767.
The shares subscribed for under the stock options have been registered in the Trade Register on 16 April 2025, as of which date the new shares will establish shareholder rights.
The shares will be traded in the Nasdaq Helsinki Plc’s First North Growth Market Finland -marketplace as an additional lot with the company’s old shares as of 17 April 2025.
The terms and conditions of stock options are available on the company's website at https://investors.aiforia.com/en/.
Further inquiries
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358 405 009 878
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com